Hi there, we see you're using OS, why not try our app?
Download
Skip to main content

Contacts and partners


We are working with colleagues in the wider NHS, regulatory and industry bodies as well as academic partners to explore COVID-19 research and trials.

General enquiries:

If you have questions about donation to the plasma programme, you can phone, text or email us.

Go to contact us

NHSBT media contact:

email: pressoffice@nhsbt.nhs.uk

Phone: 01923 367 600 (24 hours a day)

Hospitals who wish to take part in the clinical trials can register an expression of interest by contacting:

For clinical queries about NHS Blood and Transplant's provision of convalescent plasma please email us at NHSBTCustomerService@nhsbt.nhs.uk.

Our programme partners

Government departments, agencies and public bodies

Department of Health & Social Care

DHSC logo

Public Health England

PHE logo

NHS Digital

NHS Digital logo

National Institute for Health Research

NIHR logo

Universities and departments

University of Cambridge

University of Cambridge logo

King's College London

King's College London logo

University of Oxford

University of Oxford logo

Radcliffe Department of Medicine

Radcliffe Department of Medicine

Nuffield Department of Medicine

Nuffield Department of Surgical Sciences

Wellcome Trust Centre for Human Genetics

Hospitals

Guy's and St Thomas' NHS Foundation Trust

Guy's and St Thomas' NHS Foundation Trust logo

Addenbrooke's Hospital

Addenbrooke's Hospital logo

John Radcliffe Hospital 

Oxford University Hospitals logo

Blood donation services

Scottish National Blood Transfusion Service

Scottish National Blood Transfusion Service logo

Welsh Blood Service

Welsh Blood Service logo

 

Interested parties

Royal College of Pathologists

Royal College of Pathologists logo

British Society of Haematology

British Society of Haematology logo

This ground-breaking REMAP-CAP trial, conducted by NHSBT, will test whether convalescent plasma treatment can save lives and shorten intensive care unit stays.
Professor David Menon

Emeritus Senior Investigator, National Institute for Health Research

NHS Blood and Transplant is now collecting convalescent plasma for use in a randomised clinical trial as a potential treatment for COVID-19. We are investigating whether this plasma can improve survival and reduce ventilation and intensive care unit stay in COVID-19 patients. This is an exciting development as there is no proven treatment for COVID-19.
Professor David Roberts

Associate Medical Director, NHS Blood and Transplant

The REMAP-CAP trial has been specifically designed to provide answers about the best treatment options for the most seriously ill with COVID-19. It is fully adaptive, meaning that new treatments can be added as we learn more, the sample size isn’t fixed and it keeps recruiting until it finds that a treatment is better, worse, or the same as another.
Professor Anthony Gordon

NIHR Research Professor and Chief Investigator for REMAP-CAP